Who is sponsoring NCT04960306?

NCT04960306 is sponsored by University of Pecs.

What drugs are being tested in NCT04960306?

Interventions in NCT04960306: Fecal filtrate transplantation, Conventional fecal microbiota transplantation.

What condition does NCT04960306 study?

NCT04960306 studies Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection.

Is NCT04960306 still recruiting?

NCT04960306 is currently status unknown. Last updated 19 May 2023.

Last reviewed 2023-05-19 · How we verify

NCT04960306: FILTRATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection

Status unknown Phase 3 Last updated 19 May 2023

What this trial tests

Phase 3 trial testing Fecal filtrate transplantation in Clostridium Difficile Infection in 238 participants. Status unknown.

Timeline

1 November 2023

Primary endpoint
1 December 2024

1 December 2025

Quick facts

Lead sponsor	University of Pecs
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	238
Start date	1 November 2023
Primary completion	1 December 2024
Estimated completion	1 December 2025
Sites	1 location across Hungary

Drugs / interventions tested

Fecal filtrate transplantation — full drug profile →
Conventional fecal microbiota transplantation — full drug profile →

Conditions studied

Clostridium Difficile Infection — all drugs for Clostridium Difficile Infection →
Recurrent Clostridium Difficile Infection — all drugs for Recurrent Clostridium Difficile Infection →

Sponsor

University of Pecs

Who can join

18 and older, any sex, with Clostridium Difficile Infection or Recurrent Clostridium Difficile Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%). The treatment of CDI, especially the recurrent form of the disease is still considered a challenge. The FILTRATE randomized controlled trial aims to investigate the safety and efficacy of fecal filtrate transplantation in the treatment of recurrent CDI and compare it with conventional fecal microbiota transplantation (FMT).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, et al · · 2023 · cited 82× · PMID 37096495 · DOI 10.1002/14651858.cd013871.pub2

Verify or expand the search:

Other recruiting trials for Clostridium Difficile Infection

Currently open trials in the same condition.

NCT07221370 — Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients · Phase 2, PHASE3 · recruiting
NCT06703918 — Study on Clostridium Difficile Infection in Infants · recruiting
NCT04305769 — Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) · Phase 2 · recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting
NCT03562741 — Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile · NA · recruiting

Other University of Pecs trials

Trials by the same sponsor.

NCT07520877 — Effect of AED-optimized Telephone-assisted CPR Instructions on No-flow Time and Chest Compression Fraction · NA · recruiting
NCT05060731 — Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding · Phase 4 · not yet recruiting
NCT07101510 — V-CPR Under Special Circumstances · NA · completed
NCT07068503 — Study of Running Injuries and Treatment Habits in Romanian Speakers · not yet recruiting
NCT07044219 — The Effect of Chlorhexidine + Hyaluronic Acid on Postoperative Wound Healing After Lower Third Molar Removal · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04960306 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pecs
Last refreshed: 19 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04960306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing